Hirotsugu Uemura1, Naoya Masumori2, Shunji Takahashi3, Makoto Hosono4, Seigo Kinuya5, Toshiyuki Sunaya6, Tomoyo Horio7, Yutaka Okayama8, Yoshiyuki Kakehi9. 1. Department of Urology, Faculty of Medicine, Kindai University, 337-2, Ono-higashi, Osaka Sayama-City, Osaka, Japan. 2. Department of Urology, Sapporo Medical University School of Medicine, 291, Minami 1-jo Nishi 16-chome, Chuo-ku, Sapporo, Hokkaido, Japan. 3. Department of Medical Oncology, The Cancer Institute Hospital of JFCR, 3-8-31Koto-ku, AriakeTokyo, Japan. 4. Department of Radiology, Faculty of Medicine, Kindai University, 337-2, Ono-higashi, Osaka Sayama-City, Osaka, Japan. 5. Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Japan. 6. Data Sciences & Analytics, Research & Development Japan, Bayer Yakuhin, Ltd., 2-4-9 Kita-ku, Umeda, Osaka, Japan. 7. Medical Affairs Oncology, Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd., 2-4-9 Kita-ku, Umeda, Osaka, Japan. 8. Pharmacovigilance Monitoring & Governance PMS, Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd, 2-4-9 Kita-ku, Umeda, Osaka, Japan. yutaka.okayama@bayer.com. 9. Department of Urology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, Japan.
Abstract
BACKGROUND: Based on results from Japanese post-marketing surveillance, exploratory analyses were performed to investigate real-world outcomes of radium-223 for metastatic CRPC (mCRPC) according to patient characteristics. METHODS: This non-interventional, prospective study enrolled mCRPC patients selected for radium-223 treatment in clinical practice. Six-month safety and effectiveness were evaluated in subgroups who had/had not received prior chemotherapy (prior-chemo/no prior-chemo groups), and a subgroup who had not received concomitant androgen-receptor axis-targeted agents (ARATs). RESULTS: In the overall population (n = 296), the prior-chemo group (n = 126) tended to have more bone metastases, more analgesic use, and higher prostate-specific antigen values than the no prior-chemo group (n = 170). Incidences of treatment-emergent adverse events (TEAEs), drug-related TEAEs, and ≥ grade 3 drug-related hematological TEAEs were 47% vs. 53%, 25% vs. 29%, and 4% vs. 7% in the no prior-chemo and prior-chemo groups, respectively. Incidences of TEAEs (61%), drug-related TEAEs (36%), and ≥ grade 3 drug-related hematological events (12%) were numerically higher in 33 patients who had received two lines of prior chemotherapy. Multivariate analysis showed that two lines of prior chemotherapy, and hemoglobin, platelet, and lactate dehydrogenase values were baseline factors significantly related to ≥ grade 2 platelet count decreased. Safety and effectiveness in patients without concomitant ARATs (n = 201) were similar to those in the overall population. CONCLUSION: In a real-life setting, radium-223 was well tolerated irrespective of prior chemotherapy, but relatively higher incidences of TEAEs and hematotoxicities were suggested in patients with two lines of prior chemotherapy, possibly reflecting more advanced disease. Radium-223 safety and effectiveness in patients without concomitant ARATs were favorable.
BACKGROUND: Based on results from Japanese post-marketing surveillance, exploratory analyses were performed to investigate real-world outcomes of radium-223 for metastatic CRPC (mCRPC) according to patient characteristics. METHODS: This non-interventional, prospective study enrolled mCRPC patients selected for radium-223 treatment in clinical practice. Six-month safety and effectiveness were evaluated in subgroups who had/had not received prior chemotherapy (prior-chemo/no prior-chemo groups), and a subgroup who had not received concomitant androgen-receptor axis-targeted agents (ARATs). RESULTS: In the overall population (n = 296), the prior-chemo group (n = 126) tended to have more bone metastases, more analgesic use, and higher prostate-specific antigen values than the no prior-chemo group (n = 170). Incidences of treatment-emergent adverse events (TEAEs), drug-related TEAEs, and ≥ grade 3 drug-related hematological TEAEs were 47% vs. 53%, 25% vs. 29%, and 4% vs. 7% in the no prior-chemo and prior-chemo groups, respectively. Incidences of TEAEs (61%), drug-related TEAEs (36%), and ≥ grade 3 drug-related hematological events (12%) were numerically higher in 33 patients who had received two lines of prior chemotherapy. Multivariate analysis showed that two lines of prior chemotherapy, and hemoglobin, platelet, and lactate dehydrogenase values were baseline factors significantly related to ≥ grade 2 platelet count decreased. Safety and effectiveness in patients without concomitant ARATs (n = 201) were similar to those in the overall population. CONCLUSION: In a real-life setting, radium-223 was well tolerated irrespective of prior chemotherapy, but relatively higher incidences of TEAEs and hematotoxicities were suggested in patients with two lines of prior chemotherapy, possibly reflecting more advanced disease. Radium-223 safety and effectiveness in patients without concomitant ARATs were favorable.
Entities:
Keywords:
Bone metastases; Castration-resistant prostate cancer; Japanese patients; Post-marketing surveillance; Radium-223; Real-world data
Authors: Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Jean A McDougall; Aasthaa Bansal; Bernardo H L Goulart; Jeannine S McCune; Andy Karnopp; Catherine Fedorenko; Stuart Greenlee; Adriana Valderrama; Sean D Sullivan; Scott D Ramsey Journal: Oncologist Date: 2016-02-10
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: L E Howard; A M De Hoedt; W J Aronson; C J Kane; C L Amling; M R Cooperberg; M K Terris; C H Divers; A Valderrama; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2016-07-05 Impact factor: 5.554
Authors: Sabina Dizdarevic; Peter Meidahl Petersen; Markus Essler; Annibale Versari; Jean-Cyril Bourre; Christian la Fougère; Riccardo Valdagni; Giovanni Paganelli; Samer Ezziddin; Ján Kalinovský; Inga Bayh; Yong Du Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-12 Impact factor: 9.236
Authors: R Kanesvaran; E Castro; A Wong; K Fizazi; M L K Chua; Y Zhu; H Malhotra; Y Miura; J L Lee; F L T Chong; Y-S Pu; C-C Yen; M Saad; H J Lee; H Kitamura; K Prabhash; Q Zou; G Curigliano; E Poon; S P Choo; S Peters; E Lim; T Yoshino; G Pentheroudakis Journal: ESMO Open Date: 2022-07-04